HealthcareDec 2, 2022

Pemphigus Vulgaris Market

By Segment, By Region, And Segment Forecasts, 2016 – 2027

Vertical: HealthcareBase Year: 201812 Sections

Book Demo

Executive Summary

Pemphigus Vulgaris Market — Snapshot

Market Size (2016)
2016
$254.89M
Projected (2027)
2027
$756.53M
CAGR (2016–2027)
10.4%
10.4%
Key Players
105+

A pemphigus vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the normal cells and causes skin problems. Pemphigus vulgaris equally affects man and woman but middle and old age people are more likely to develop this condition.

The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, increasing geriatric population. Increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment and lack of awareness are expected to restrain the market growth

Key Insight

The Pemphigus Vulgaris Market market is projected to grow at a CAGR of 10.4% from 2016 to 2027.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

Geographic Coverage: This analysis covers 4 regions: Europe, Asia Pacific, Rest of the World, Americas.
Market Segmentation: The market is analyzed across 5 segments: Immunosuppressants, Corticosteroids, Intravenous Immunoglobulin (IVIG) Therapy, Biological Therapies, Others. Forecasts are provided for each segment from 2016 to 2027.
Competitive Landscape: 105 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Pemphigus Vulgaris Market — Growth Trajectory

The scope of the global pemphigus vulgaris market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on treatment, route of administration, end user, end user, and region.

Pemphigus Vulgaris Market — Growth Trajectory

Immunosuppressants

Corticosteroids

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

Treatment Type is broken down into: Corticosteroids, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy, Others.
Route of Administration is broken down into: Oral, Subcutaneous, Intravenous.
End User is broken down into: Hospitals & Clinics, Specialty Dermatology Clinics, Research & Academic Laboratories.

Geographic Analysis

Regional market breakdown

Europe Europe market size reached $97.90M in 2016 and is projected to reach $290.89M by 2027, growing at a CAGR of 10.4%.
Asia Pacific Asia Pacific market size reached $37.11M in 2016 and is projected to reach $112.58M by 2027, growing at a CAGR of 10.6%.

Rest of the World Rest of the World market size reached $11.34M in 2016 and is projected to reach $27.33M by 2027, growing at a CAGR of 8.3%.
Americas Americas market size reached $108.54M in 2016 and is projected to reach $325.73M by 2027, growing at a CAGR of 10.5%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Pemphigus Vulgaris Market — How We Researched This Market

This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.

Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2027
Primary Interviews
150+

Research Process

Historical data (2016–2018) and forecast period (2018–2027)

Problem Definition

Market scoping
Objective setting
Framework design

Secondary Research

Literature review
Data mining
Trend analysis

Primary Research

Expert interviews
Field visits
Surveys

Data Analysis

Quantitative modeling
Statistical testing
Validation

Insights & Reporting

Synthesis
Recommendations
Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)

Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Pemphigus Vulgaris Market — Competitive Analysis

Bargaining Power of Suppliers

argaining power of suppliers in the pemphigus vulgaris market is medium. In global pemphigus vulgaris industry, suppliers are raw materials manufacturers and, intermediate original equipment manufacturers (OEMs). There is a high number of suppliers in the global pemphigus vulgaris market thus leading to a moderate amount of bargaining power in the market. Switching cost of these suppliers is also medium as the suppliers tend to enter into long-term associations with the manufacturers.

Bargaining Power of Buyers

The bargaining power of buyers is low to medium in the pemphigus vulgaris market. Patients are the major buyers for the market. The presence of buyers in the market is high due to the increasing prevalence of autoimmune diseases and the growing burden of immunological diseases. In addition, buyers are price sensitive, which moderately affects their bargaining power in the market. There is a presence of a high number of antibacterial drug manufacturers in the world, which provides products at a low cost. Additionally, switching cost is moderate for buyers as many alternative treatments are available at an effective cost.

Threat of New Entrants

The threat of new entrants is medium to high in the pemphigus vulgaris market. Any company manufacturing the drug for pemphigus vulgaris which is trying to enter the market is required to abide by mandatory regulatory standards. The pemphigus vulgaris drug manufacturing market is also characterized by a high degree of brand loyalty where establishing a brand name is difficult for newcomers. However, government support and presence of huge opportunities in the market has encouraged many players to invest in this lucrative market. These factors are responsible for reducing the barrier for entrance on new companies which can be a major threat for the current companies.

Threat of Substitutes

The threat of substitutes in the global pemphigus vulgaris market is Medium. Substitutes are the different types of generic and other drugs, which completely dependent on the efficacy and the cost of the drug. Buyer propensity to substitute is low as most of the medical professionals prescribe a limited number of drugs.

Intensity of Rivalry

The degree of competition in the pemphigus vulgaris market is medium. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Pemphigus vulgaris drug manufacturing companies are trying to develop less expensive drugs to make treatment more affordable in the developing region. Moreover, brand loyalty moderately affects the market as buyers are more inclined towards established manufacturers. To overcome the competition, players are focusing on the development of new products to withstand the increasing competition. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Pemphigus Vulgaris Market.

Regional Market Size (USD Mn)

Market estimates by geography (2027)

USD Mn

InsightAmericas leads with $325.73M by 2027, while Asia Pacific is projected to grow fastest at a 10.6% CAGR.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION	2016	2018	2027	CAGR	SHARE
Europe	$97.90M	$193.72M	$290.89M	10.4%	38%
Asia Pacific	$37.11M	$74.27M	$112.58M	10.6%	15%
Rest of the World	$11.34M	$20.13M	$27.33M	8.3%	4%
Americas	$108.54M	$215.95M	$325.73M	10.5%	43%
Total	$254.89M	$504.07M	$756.53M	10.4%	100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Segment Revenue (2027)

Immunosuppressants

Corticosteroids

Intravenous Immunoglobulin (IVIG) Therapy

Biological Therapies

Others

067133200266

Immunosuppressants32%
Corticosteroids27%
Intravenous Immunoglobulin (IVIG) Therapy24%
Biological Therapies13%
Others4%

Total Market Size

$756.54M

Market by Segment (2027)

APPLICATION	REVENUE ($B)	GROWTH RATE	MARKET PENETRATION
Immunosuppressants	$241.58M	10.4%	77%
Corticosteroids	$205.28M	10.4%	72%
Intravenous Immunoglobulin (IVIG) Therapy	$179.54M	10.4%	47%
Biological Therapies	$96.83M	10.4%	85%
Others	$33.31M	10.4%	53%

* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Empower your Business
with Insights

Save over 20% on
Annual Subscription

Subscribe now

Book a demo

See plans for professionals or small and medium businesses.

Analytics

Pemphigus Vulgaris Market — Key Findings

Analytical insights on Pemphigus Vulgaris Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Pemphigus Vulgaris Market market is projected to reach $756.53M by 2027, growing at 10.4% CAGR. The Immunosuppressants segment holds the largest share.

Market Dynamics

A pemphigus vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the normal cells and cause skin problems. Pemphigus vulgaris equally affects man and woman but middle and old age people are more likely to develop this condition.

The increasing prevalence of pemphigus vulgaris globally, growing financial support by various private and government organizations for research of diseases, and increasing geriatric population are driving the global pemphigus vulgaris market. However, lack of awareness among countries and the high cost of treatment are expected to hamper the growth of this market during the forecast period. Nevertheless, advancements in treatments are set to be a lucrative opportunity for the growth of this market in the near future.

Market Drivers

Pemphigus vulgaris is one of the life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe, with approximately 0.7 to 5 people per 1,000,000 per year in the overall population. It was also mentioned that pemphigus foliaceous, a form of pemphigus vulgaris, has a high prevalence in Africa and some rural areas in the world. Similarly, according to the International Pemphigus & Pemphigoid Foundation, the incidence of pemphigus was high within China with approximately 0.5 to 3.2 people per 100,000 per year in the overall population.

According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were encountered with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the world is expected to drive market growth during the forecast period. Thus, the high number of incidences of pemphigus vulgaris would support market growth during the forecast period.

Market Opportunities

The number of people suffering from pemphigus vulgaris is increasing globally, and the complication and severity related to this condition are also rising. According to the South African Dental Association (SADA) 2018, the study on oral pemphigus vulgaris with skin and ocular involvement mentioned that laser therapy could be used as an alternative method to treat pemphigus vulgaris which is an effective method with fewer side effects. The increase in advancements in treatments is likely to enhance the market growth.

Market Restraints

Pemphigus vulgaris is most common in developing countries than in developed countries, as most of the population living in developing countries are not aware of dermatological problems. The number of cases registered in developing countries is high as compared to the cases occurring in developed countries. According to the National Organization for Rare Disorders (NORD) 2015 Endemic pemphigus (Fogo Selvagem), a form of pemphigus occurred in a large number of people living in Central and South America, especially countryside areas of Brazil and also occurred in different rural areas of the world. The lack of awareness about the treatment among the population is likely to hinder the market growth.

Market Challenges

The initial step in the therapeutic management of pemphigus vulgaris is to control diseases, restore the affected areas, and reduce the damage or spreading of infections. The main challenge in the long-term treatment is the side effects associated with the treatment and adverse effects of immunosuppressive agents. According to the National Center for Biotechnology Information 2016, side-effects associated with the use of corticosteroids for the treatment of pemphigus vulgaris include osteoporosis, diabetes, tension, increased weight, abnormal liver function test, fungal and viral infection, hyperkalemia, cataract, and myopathy. Such side effects and complications of treatments could affect the pemphigus vulgaris market negatively.

Strategic Outlook and Future Directions

Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.

Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.

Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.

Market Value by Segment (2027)

Value (USD Mn)

Immunosuppressants

Corticosteroids

Intravenous Immunoglobulin (IVIG) Therapy

Biological Therapies

Others

Companies

Key companies profiled in Pemphigus Vulgaris Market

Profiles of 105 companies operating in the Pemphigus Vulgaris Market market, including revenue, employee count, and market positioning where available.

Region

Industry

Founded Year

Showing 105 of 105 companies

BIOGEN INC

BIOGEN INC.

Healthcare

Company Headquarters: Massachusetts, US Founded: 1978 Workforce: 7,800 Company Working: Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers drugs for the treatment of multiple sclerosis, plaque psoriasis spinal muscular atrophy, non-Hodgkin's lymphoma, Chronic Lymphocytic Leukemia (CLL), and among other conditions. The company offers products through its sales force and marketing groups. It has strategic collaborations with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. The firm has a strong presence in North America, Europe, Asia-Pacific, and

Company Headquarters: Breda, The Netherlands Founded: 2008 Workforce: 105 Company Working: argenx SE is a clinical-stage biotechnology company. It is developing a pipeline of differentiated antibody-based therapies for the treatment of autoimmune diseases and cancer. The company focuses on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known to treat diseases with significant unmet medical needs. It has a strong presence in Luxembourg, Denmark, Switzerland, and the Netherlands.

Breda, The Netherlands

Novartis A

Novartis AG

Healthcare

Company Headquarters: Basel‎, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.

CABALETTA BIO

Company Headquarters: Philadelphia, US Founded: 2017 Workforce: ~ 10-50 Company Working: Cabaletta Bio (Cabaletta) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. The company’s CABA platform, has applicability across more than two dozen B cell-mediated autoimmune diseases.

INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)

Healthcare

Company Headquarters: Ahmedabad, India Founded: 1984 Workforce: ~ 350 Company Working: Intas Pharmaceuticals Ltd (Intas) is a vertically integrated global pharmaceutical formulation developing, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella named Accord Healthcare to operate in global markets. Accord's portfolio comprises a multitude of different pharmaceutical forms, including, tablets, capsules, cytotoxic injectables, non- cytotoxic (ampoules), and controlled drugs.

PRINCIPIA BIOPHARMA

Company Headquarters: South San Francisco, CA (US) Founded: 2008 Workforce: ~57 Company Working: Principia Biopharma (Principia) functions as a late-stage biopharmaceutical company focused on developing novel therapies for serious immune mediated diseases. The company offers and develops drugs for the treatment of cancer. The company serves the US market. Principia Biopharma patented tailored covalency platform allows to develop and design small covalent molecules.

South San Francisco, CA (US)

Page 1 of 18

…

Go to page

About the Author

Pharmaceutical Research Team

Healthcare · Pharmaceutical

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print. This report specifically covers the Pharmaceutical space within that portfolio.

Similar Reports

View all

HealthcareJul 31, 2026

Vietnam Oncology Drugs Market

HealthcareJul 31, 2026

US Occupational Medicine Market

HealthcareJul 31, 2026

US Occupational Health Market

Powering the world's best teams.
From next-gen startups to established enterprises.

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Pemphigus Vulgaris Market

By Segment, By Region, And Segment Forecasts, 2016 – 2027

Starting from

$4,950

Pemphigus Vulgaris Market

By Segment, By Region, And Segment Forecasts, 2016 – 2027

Key Insight

Market Performance Trend

Market Scope & Coverage

What this report covers

Pemphigus Vulgaris Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Pemphigus Vulgaris Market — Competitive Analysis

Regional Market Data

Segment Revenue (2027)

Segment Market Share

Market by Segment (2027)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Market Challenges

Strategic Outlook and Future Directions

Market Value by Segment (2027)

About the Author

Pharmaceutical Research Team

Market Performance Trend

Pemphigus Vulgaris Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Pemphigus Vulgaris Market — Competitive Analysis

Regional Market Data

Segment Revenue (2027)

Segment Market Share

Market by Segment (2027)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Market Challenges

Strategic Outlook and Future Directions

Market Value by Segment (2027)

About the Author

Pharmaceutical Research Team

Save over 20% on
Annual Subscription

Save over 20% on
Annual Subscription